Browse Articles

Discover research articles across all indexed journals

RUL-DBRS: A Novel Energy Efficient and Robust Protocol for Enhanced Communication in Underwater Wireless Sensor Networks

Scientific Reports Abdul Salam, Shahab Haider, Noreen Khan et al. Jun 20, 2026 DOI: 10.1038/s41598-026-54861-x

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1

Journal of Clinical Oncology Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm et al. Jun 20, 2026 DOI: 10.1200/jco-26-00842

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline .

A blockchain-enabled trust-aware authentication framework for secure communication in VANETs

Scientific Reports S. Sajini, V. Jananee, E. A. Mary Anita Jun 20, 2026 DOI: 10.1038/s41598-026-51446-6

Abstract Vehicular Ad Hoc Networks (VANETs) are essential for intelligent transportation systems; however, their dynamic topology and open wireless communication environment expose them to impersonation, Sybil, replay, and message modification attacks. Existing authentication schemes mainly rely on centralized authorities and conventional cryptographic mechanisms, which lack dynamic trust evaluation and fail to ensure secure authentication during Roadside Unit (RSU) handover and cluster mobility. To address these challenges, this paper proposes a blockchain-enabled trust-aware authentication framework for secure VANET communication. The framework integrates a Joint Probability and Error Unit-based Deep Learning Neural Network (JPEU-DLNN) for dynamic trust assessment and Log-based Edwards Curve Cryptography (LECC) for lightweight key generation. In addition, Gini Indexed Farthest First Clustering (GIFFC) ensures stable cluster formation, while the Directional Gannet Optimization Algorithm (DGOA) supports optimal routing. Blockchain technology provides decentralized and immutable credential storage, eliminating single-point failure and certificate forgery. Simulation results show that the proposed framework achieves 95.62% authentication accuracy and 96.94% packet delivery ratio, with reduced end-to-end delay and improved network lifetime compared to existing blockchain-based authentication schemes. Security evaluation confirms strong resistance against active and passive attacks. These results demonstrate the practical applicability of the framework for secure and reliable VANET deployments.

Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS

Journal of Clinical Oncology Jian Huang, Zheng-Fu Xie Jun 20, 2026 DOI: 10.1200/jco-25-02755

Efficiency of a microplastic removal system from synthetic wastewater using a chemical process combined with simple filtration

Scientific Reports Poonyaporn Poolborwornrak, Santisith Khiewkhern, Jindawan Wibuloutai et al. Jun 20, 2026 DOI: 10.1038/s41598-026-59084-8

Abstract Microplastic contamination in freshwater ecosystems poses a critical environmental challenge, necessitating effective removal technologies in wastewater treatment. This research aims to evaluate the efficiency of a hybrid removal system for polyethylene microplastics (particle sizes 0.15–1 mm) by integrating chemical coagulation with simple sand filtration. The performance of three coagulants—alum, polyaluminium chloride (PAC), and ferric chloride—supplemented with chitosan as a coagulant aid, was optimized across various dosages and pH levels, followed by the evaluation of a sand filter column under different flow rates. The results indicated that coagulation efficacy was pH-dependent, peaking at pH 7, where PAC achieved the highest removal efficiency of 77.41 ± 4.47% for fine 0.15 mm particles, followed by alum (73.22 ± 3.54%) and ferric chloride (63.18 ± 3.63%); notably, the combined system operating at a flow rate of 15 mL/min (Experimental Set 1) attained an exceptional overall removal efficiency of 99.93%. These findings demonstrate that coupling chemical coagulation with low-cost sand filtration offers a robust and scalable solution for significantly reducing microplastic discharge in synthetic wastewater applications.

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

Journal of Clinical Oncology Rana R. McKay, Wanling Xie, Archana Ajmera et al. Jun 20, 2026 DOI: 10.1200/jco-25-02835

PURPOSE Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223. PATIENTS AND METHODS Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223 (55 kBq/kg intravenous once every 4 weeks × 6 doses) or radium-223. Crossover was allowed at progression. The primary end point was investigator-assessed radiographic progression-free survival (rPFS). RESULTS A total of 120 patients were randomly assigned. Most had prior androgen receptor pathway inhibitor exposure (96%), 52% had received docetaxel, 47% had >20 BM, and 90% received bone-protecting agents. The combination significantly improved rPFS (median 8.9 v 4.7 months; hazard ratio [HR], 0.50 [one-sided 90% CI, 0.35 to 0.70]; one-sided P = .0042). The benefit was most pronounced in patients without prior docetaxel (13.7 v 5.7 months; HR, 0.24 [90% CI, 0.15 to 0.40]) and those with ≤20 BM (13.4 v 4.2 months; HR, 0.21 [90% CI, 0.13 to 0.33]). The 1-year cumulative incidence of symptomatic skeletal-related events was lower with the combination (12.7% v 22.9%). Median overall survival was similar (20.2 v 21.1 months). Grade ≥3 treatment-related adverse events occurred in 56% versus 33% (combination v radium-223), primarily hematologic, including lymphopenia (31% v 9.1%), anemia (22% v 16%), and thrombocytopenia (6.8% v 3.6%). CONCLUSION Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage–targeted strategies in this population.

Design, modification, and manufacture of animal-drawn secondary tillage implements for wheat-based light soil farming systems in Misrak Bedawacho District, Central Ethiopia

Scientific Reports Darebe Yohannes, Kishor Purushottam Kolhe, Mihret Dananto et al. Jun 20, 2026 DOI: 10.1038/s41598-026-58639-z

Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial

Journal of Clinical Oncology Ismail Gögenur, Tobias F. Justesen, Line S. Tarpgaard et al. Jun 20, 2026 DOI: 10.1200/jco-25-02274

PURPOSE Neoadjuvant immune checkpoint inhibition has shown promise in localized deficient mismatch repair (dMMR) colorectal cancer, yet the optimal treatment duration, regimen, and methods for response evaluation remain undefined. This trial aimed to investigate the efficacy and safety of neoadjuvant pembrolizumab for patients with localized dMMR colon cancer. METHODS Participants received a single cycle of pembrolizumab (4 mg/kg, max 400 mg, every-6-weeks dosing regimen), followed by a preoperative endoscopy with biopsies and surgery 3-5 weeks later. The primary end point was pathologic complete response (pCR); secondary and exploratory end points included major pathologic response (MPR), safety, survival, and endoscopic response assessment. RESULTS From February 2023 to March 2024, 85 patients (median age 74 years) were enrolled. All received pembrolizumab; one patient declined surgery. Among 84 patients, pCR was achieved in 44% (37 of 84; 95% CI, 33 to 55), and MPR in 57% (48 of 84; 95% CI, 46 to 68). Two (2%) patients died of complications within 30 days of surgery. At a median follow-up of 18.4 months (IQR, 16.3-21.1), one patient had a recurrence, resulting in overall and disease-free survival rates of 98% and 96%. Grade 3 adverse events occurred in 11% of patients (9 of 85; 95% CI, 3 to 16), with three treatment-related events. In 81 patients, the sensitivity, specificity, and accuracy of the biopsies for predicting pCR were 68%, 75%, and 72%, respectively. In 76 patients, the sensitivity, specificity, and accuracy of the endoscopic images for predicting pCR were 77%, 93%, and 86%, respectively. CONCLUSION A single cycle of neoadjuvant pembrolizumab led to pCR in nearly half of patients undergoing surgery for localized dMMR colon cancer. The utility of endoscopic evaluation may inform future strategies for patient selection in nonoperative management pathways.

Self-assembly of polyvinylidene fluoride (PVDF) and carbon nanotubes into flexible piezoelectric nanofiber transducers

Scientific Reports Cherif M. Azzaz, Nicole R. Demarquette, Ricardo J. Zednik Jun 20, 2026 DOI: 10.1038/s41598-026-58811-5

Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno

Journal of Clinical Oncology Juliet Gray, Rebekah Weston, Simon Gates et al. Jun 20, 2026 DOI: 10.1200/jco-26-00237

Development of an anemia detection model in emergency departments using lip region images based on medical knowledge and deep learning technology

Scientific Reports Zhaofan Li, Yugui Zhang, Yuhang Tian et al. Jun 20, 2026 DOI: 10.1038/s41598-026-40210-5

Abstract Anemia’s high global prevalence and socio-economic burden necessitate early diagnosis, yet reliance on invasive blood testing creates significant barriers to diagnosis and treatment. To address this, we developed a deep learning model using the Detection Transformer framework for the rapid, non-invasive assessment of anemia severity in a real-world emergency department setting. Comparing a lip-focused model to a full-face approach, the former proved superior, achieving 85.0% accuracy. This significantly outperformed the full-face model (77.0%) and clinical judgments by both senior (59.3%) and junior (49.95%) physicians, with a rapid processing time of 127.50 ms. By integrating key medical knowledge to classify anemia into three severity levels, our model surpasses clinician performance, demonstrating its potential as a powerful, automated tool for clinical decision support.

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1

Journal of Clinical Oncology Joshua E. Reuss, Nofisat Ismaila, Amith Ahluwalia et al. Jun 20, 2026 DOI: 10.1200/jco-26-00843

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .

Pyrite-assisted mechanochemical leaching of chalcopyrite concentrate in sulfuric acid under non-oxidative conditions

Scientific Reports Mohammad Tahami, Vahideh Shojaei, Mahin Schaffie et al. Jun 20, 2026 DOI: 10.1038/s41598-026-58699-1

Long-Term Efficacy and Safety of Taletrectinib in Patients With <i>ROS1</i> + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study

Journal of Clinical Oncology Wei Li, Yongchang Zhang, Huijie Fan et al. Jun 20, 2026 DOI: 10.1200/jco-26-00434

Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) with activity against the ROS1 G2032R resistance mutation. Initial data from the TRUST-I study (ClinicalTrials.gov identifier: NCT04395677 ) demonstrated high response rates and intracranial (IC) activity, with promising durability, in Chinese patients with advanced ROS1 + non–small cell lung cancer (NSCLC). With longer follow-up, taletrectinib continued to demonstrate high and durable response rates in both TKI-naïve and crizotinib-pretreated patients, including IC activity and promising overall survival (OS). Among 103 TKI-naïve patients who started taletrectinib at 600 mg once daily (median follow-up, 51.0 months), the objective response rate (ORR) was 90.3% (95% CI, 82.9 to 95.3), the median duration of response (DOR) and median progression-free survival (PFS) exceeded 4 years (49.7 months and 49.6 months, respectively), and median OS was not reached. Among 66 crizotinib-pretreated patients (median follow-up, 45.2 months), the ORR was 51.5%, the median DOR was 13.2 months, the median PFS was 7.6 months, and the median OS was 25.6 months. The safety profile remained consistent with prior reports, and no new safety signals were identified. Overall, taletrectinib demonstrated durable long-term efficacy and a manageable safety profile in patients with advanced ROS1 + NSCLC.

Thymoquinone attenuates tricyclazole-induced testicular dysfunction through endocrine, redox, histomorphometric and sperm function changes in rats

Scientific Reports Ramona Kasra Kermanshahi, Seyyed Gholam Ali Jorsarayi, Esmail Fattahi et al. Jun 20, 2026 DOI: 10.1038/s41598-026-58649-x

Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition

Journal of Clinical Oncology Linda D. Bosserman, Don S. Dizon Jun 20, 2026 DOI: 10.1200/jco-25-03121

Development and multi-institutional validation of a deep learning algorithm for predicting cervical cord compression using dynamic cervical lateral radiographs

Scientific Reports Sung Cheol Park, Wounsuk Rhee, Bong-Soon Chang et al. Jun 20, 2026 DOI: 10.1038/s41598-026-56657-5

Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma

Journal of Clinical Oncology Karla V. Ballman Jun 20, 2026 DOI: 10.1200/jco-26-00444

Relationship between sleep, stress and psychological distress in internally displaced persons depends on the length of displacement

Scientific Reports Tamar Basishvili, Marine Eliozishvili, Nani Lortkipanidze et al. Jun 20, 2026 DOI: 10.1038/s41598-026-57241-7

Abstract In recent years, the number of refugees and internally displaced persons (IDPs) has dramatically grown worldwide. We aimed to examine psychological distress and its association with sleep and stress in two groups of IDPs with different lengths of displacement in comparison with the general population. Forty-five individuals displaced in 2008, 2.5 months before this study (2008 IDPs), 67 respondents displaced in 1993 (1993 IDPs), and 53 individuals from Tbilisi general population were assessed. All study participants completed the Insomnia Severity Index (ISI), Perceived Stress Scale (PSS) and Brief Symptom Inventory (BSI). Sociodemographic information such as age, sex, education level and marital status, was collected. The groups differed significantly on age, education, marital status, ISI, PSS, and Global Severity Index (GSI). The highest mean ISI and PSS scores were found for the 2008 IDPs, while the highest GSI score was observed in 1993 IDPs, although the GSI and PSS scores did not differ between the two groups of IDPs. The proportion of people with a GSI T score ≥ 63 was 47.2% in the general population, 71.6% in the 1993 IDPs, and 64.4% in the 2008 IDPs. The ISI and PSS were significant predictors of the GSI in all groups. The PSS exhibited the highest predictive power for 2008 IDPs (β = 0.429), while the ISI - in 1993 IDPs (β = 0.417). Psychological distress persists over time in IDPs. Although both stress and insomnia are strongly associated with psychological distress, perceived stress appears to have a stronger impact in the early resettlement period, whereas insomnia emerges as a more prominent predictor later, years after displacement. Therefore, sleep health in displaced population, and on a broader scale in individuals subjected to traumatic events, warrant attention in long-term perspective for implementing targeted interventions and effectively addressing well-being of affected individuals.

Prognostic value of on-admission IL-6, lactate, base deficit, ESR, and CRP in a prospective study of multiple trauma patients

Scientific Reports Behrad Eftekhari, Anita Khalili, Mohammad Taghi Ashoobi et al. Jun 20, 2026 DOI: 10.1038/s41598-026-58481-3